The COVID coronavirus is setting this little known company up for great success. Shares of Relief Therapeutics (OTC:RLFTF) is still relatively low, so investors still have a chance of getting in on the ground floor. The company recently updated their website which provides more information about their business and their pipeline.
Relief Therapeutics enters Coronavirus Technology Watch Program
RLF-100™ has a 20-year history of safe use in humans in multiple human trials for sarcoidosis, pulmonary fibrosis, asthma/allergy, and pulmonary hypertension. It has been shown in more than 100 peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury and inflammation.
RLF-100™ is currently in clinical testing for acute lung injury (ALI) associated with the SARS-CoV-2 virus (COVID-19).
Relief devised a swift plan of action to respond to one of the largest healthcare disasters our time by rapidly advancing RLF-100™ towards approval in COVID-19-induced lung injury. Through its multimodal mechanism of action, RLF-100™ may uniquely target the pathways attacked by the SARS-CoV-2 virus (COVID-19), preventing acute lung injury (ALI).
COVID-19-related death is primarily caused by respiratory failure. Before this acute phase, however, there is evidence of early viral infection of the alveolar type 2 cells. These cells are known to have angiotensin converting enzyme 2 (ACE2) receptors at high levels, which serve as the route of entry for the SARS-CoV-2 into the cells. Coronaviruses are shown to replicate in alveolar type 2 cells, but not in the more numerous type 1 cells. These same type 2 alveolar cells have high concentrations of VIP receptors on their cell surfaces giving rise to the hypothesis that VIP could specifically protect these cells from injury.
Injury to the type 2 alveolar cells is an increasingly plausible mechanism of COVID-19 disease progression. (Mason 2020). These specialized cells replenish the more common type 1 cells that line the lungs. More importantly, type 2 cells manufacture surfactant that coats the lung and are essential for oxygen exchange. Other than RLF-100™, no currently proposed treatments for COVID-19 specifically target these vulnerable type 2 cells.
RLF-100™ specifically targets alveolar type 2 (AT2) cells in the lung. The company is objective in establishing RLF-100™ as the standard of care for intensive care units (ICUs) in acute as well as chronic contexts to prevent and cure respiratory failure and its complications.
RLF-100™ will prevent lung fibrosis and pulmonary sarcoidosis based on their recent studies.
Relief Therapeutics (OTC:RLFTF) seeking new partnerships
To bring new therapeutic options to the market as quickly as possible, Relief is seeking partnerships with companies who have late-stage clinical assets that can be rapidly advanced.
Criteria to evaluating new assets include:
- A focus on the development of peptides and biologics medicinal product candidates,
- Molecules already assessed in human subjects with an excellent safety profile and
- Short, capital-efficient clinical trials with objective endpoints.
Should you invest in Relief Therapeutics (OTC:RLFTF)?
Shares of Relief Therapeutics (RLFTF) appear to be a very good investment option, the Money Midnight Indicator is expecting its price to increase considerably in the next of years. The majority of the metrics point to this investment being highly attractive.
